ScholarIQanswers from OpenAlex & ORCID
Rodney Sinclair
ResearcherPublications, citations & collaboration network
Rodney Sinclair is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Rodney Sinclair have?
ScholarIQindexed works
Rodney Sinclair has 843 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Rodney Sinclair have?
ScholarIQcitation count
Rodney Sinclair has 23,840 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Rodney Sinclair?
ScholarIQh-index
Rodney Sinclair has an h-index of 76 in OpenAlex.
What is the i10-index of Rodney Sinclair?
ScholarIQi10-index
Rodney Sinclair has an i10-index of 378 in OpenAlex.
What is the ORCID of Rodney Sinclair?
ScholarIQorcid
The ORCID for Rodney Sinclair is on the source record.
What is the OpenAlex record for Rodney Sinclair?
ScholarIQopenalex
The OpenAlex for Rodney Sinclair is on the source record.
What are the most-cited papers on Rodney Sinclair?
ScholarIQmost cited works
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich, Kim Papp, Andrew Blauvelt, Stephen K. Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, N. Cichanowitz, Qing Li, Kenneth Liu, Carmen La Rosa, Stuart Green, Alexa B. Kimball
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Eric L. Simpson, Rodney Sinclair, Seth Forman, Andreas Wollenberg, Roland Aschoff, Michael J. Cork, Thomas Bieber, Jacob P. Thyssen, Gil Yosipovitch, Carsten Flohr, Nina Magnolo, Catherine Maari, Claire Feeney, Pinaki Biswas, Svitlana Tatulych, Hernán Valdez, Ricardo Rojo
Development and validation of the International Hidradenitis Suppurativa Severity Score System ( <scp>IHS</scp> 4), a novel dynamic scoring system to assess <scp>HS</scp> severity
Christos C. Zouboulis, Thrasyvoulos Tzellos, Αthanassios Kyrgidis, Gregor B. E. Jemec, Falk G. Bechara, Evangelos J. Giamarellos‐Bourboulis, John R Ingram, Theodora Kanni, Ioannis Karagiannidis, Antonio Martorell, Łukasz Matusiak, Andreas Pinter, Errol P. Prens, Dagmar Presser, Sylke Schneider‐Burrus, Esther von Stebut, Jacek C. Szepietowski, Hessel H. van der Zee, Sophia Wilden, Robert Sabat, Rodney Sinclair, Dunja Ana Vekic, P. De Haes, V. del Mármol, Afsáneh Alavi, Wayne Gulliver, Aude Nassif, Georgios Nikolakis, Maurizio Podda, C. Antoniou, Florentina Delli, Clio Dessinioti, Aikaterini Patsatsi, Anastasia Trigoni, C. Zisimou, Vincenzo Bettoli, Simone Garcovich, Jurr Boer, Barbara Horváth, G. Ingvarsson, L. Puig, Robert E. Hunger, Lennart Emtestam, F. William Danby, Alexa B. Kimball
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Thomas Bieber, Eric L. Simpson, Jonathan I. Silverberg, Diamant Thaçi, C. Paul, Andrew Pink, Yoko Kataoka, Chia‐Yu Chu, Marco DiBonaventura, Ricardo Rojo, Jeremias Antinew, Ileana A. Ionita, Rodney Sinclair, Seth Forman, Jacek Zdybski, Pinaki Biswas, Bimal Malhotra, Fan Zhang, Hernán Valdez
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi, Z. Reguiaï, Alice B. Gottlieb, Falk G. Bechara, C. Paul, Evangelos J. Giamarellos Bourboulis, A. Villani, Andreas Schwinn, Franziska Ruëff, Larisha Pillay Ramaya, Adam Reich, Inês Lobo, Rodney Sinclair, Thierry Passeron, Antonio Martorell, Pedro Mendes‐Bastos, Georgios Kokolakis, Pierre‐André Bécherel, Magdalena B. Wozniak, Angela Llobet Martinez, Xiaoling Wei, Lorenz Uhlmann, Anna Passera, Deborah Keefe, Ruvie Martin, Clarice Field, Li Chen, Marc Vandemeulebroecke, Shoba Ravichandran, Elisa Muscianisi